LPCN Lipocine
- 5.0700
- +0.1500+3.05%
Lipocine News
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154
Pivotal study design aligned with FDA on streamlined pathway to NDA submission goal in 2024Topline results anticipated late in 2Q 2024SALT LAKE CITY, May 1, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ:
Lipocine Initiates New ATM Offering, Ends Previous Agreement
Lipocine Says LPCN 2401 Shows Improved Body Composition in Mid-Stage Trial
Lipocine (LPCN) said Thursday that a phase 2 trial of LPCN 2401 showed improved body composition in participants with obesity. LPCN 2401 demonstrated increased lean mass by 4.4% and reduced fat mass b
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersEliem Therapeutics (NASDAQ:ELYM) stock moved upwards by 51.6% to $4.05 during Thursday's pre-market session. The market value of their outstanding shares is at $112.2 million. Rallybio (NASDAQ:
Lipocine Reports Positive Results From Obesity Treatment Trial
Top Premarket Gainers
Rallybio Corp. (RLYB) shares nearly doubled Thursday premarket after the company said it formed a collaboration with Johnson & Johnson to develop therapies for pregnant women at risk of fetal and neon
Lipocine Announced Results From A Phase 2 Trial Of LPCN 2401 Showing Significant Improvement In Body Composition Through Decreased Fat Mass And Increased Lean Mass Or Fat-free Mass In Obese Patients With At Least One Weight-related Comorbidity
Lipocine Announced Results From A Phase 2 Trial Of LPCN 2401 Showing Significant Improvement In Body Composition Through Decreased Fat Mass And Increased Lean Mass Or Fat-free Mass In Obese Patients With At Least One Weight-related Comorbidity
Lipocine: LPCN 1148 Meets Primary And Hepatic Encephalopathy Endpoints In Phase 2 Study
Lipocine Announces Positive Week 52 Results From LPCN 1148 Phase 2 Study in Patients With Cirrhosis
Met primary and Hepatic Encephalopathy (HE) endpoints in Phase 2 studyIncrease in Skeletal Muscle Index (SMI) observed at Week 24 was maintained through 52 weeksParticipants on placebo increased SMI w
Lipocine Doses First Group in Pivotal Study of Potential Postpartum Depression Drug
Lipocine (LPCN) said Monday that it has completed enrollment and dosed the first group of participants in the pivotal pharmacokinetic study of drug candidate LPCN 1154, or oral brexanolone, to treat p
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
Company anticipates topline results from this crossover pivotal study late in the second quarter of 2024SALT LAKE CITY, March 25, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersMolina Healthcare (NYSE:MOH) stock moved upwards by 24.2% to $503.11 during Wednesday's after-market session. The company's market cap stands at $29.3 billion. Evoke Pharma (NASDAQ:EVOK) shares
Lipocine GAAP EPS of -$3.14
Press Release: Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023 PR Newswire SALT LAKE CITY, March 7, 2024 SALT LAKE CITY, March 7, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN),
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
SALT LAKE CITY, March 7, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") disorders, today announced financial results
Lipocine to Present at 36th Annual Roth Conference
SALT LAKE CITY, March 6, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that Dr. Mahesh V. P
Lipocine Announces Key Study Dosing for Postpartum Depression Treatment
Lipocine Announces Confirmation Of Dosing Regimen For Pivotal Study Of LPCN 1154
Positive clinical study results confirm 48-hour dosing regimen for the pivotal PK studyOn track for Q2-24 pivotal study topline results and planned Q4-24 NDA filing SALT LAKE CITY, Feb. 6, 2024 /PRNew
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154
Positive clinical study results confirm 48-hour dosing regimen for the pivotal PK studyOn track for Q2-24 pivotal study topline results and planned Q4-24 NDA filing SALT LAKE CITY, Feb. 6, 2024 /PRNew
Lipocine Announces Continued Commercialization of TLANDO® Through Verity Pharmaceuticals
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that...
Analysis
Price Target
No Data
